☰

Paola Grandi - Publications

Affiliations: 
University of Pittsburgh, Pittsburgh, PA, United States 
Area:
glioma, Oncolytic vectors, HSV
Tree Info Similar researchers PubMed Report error

43 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Peters C, Grandi P, Nigim F. Updates on Oncolytic Virus Immunotherapy for Cancers. Molecular Therapy Oncolytics. 12: 259-262. PMID 33072862 DOI: 10.1016/J.Omto.2019.01.008  0.473
2019 Sette P, Amankulor N, Li A, Marzulli M, Leronni D, Zhang M, Goins WF, Kaur B, Bolyard C, Cripe TP, Yu J, Chiocca EA, Glorioso JC, Grandi P. GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival. Molecular Therapy Oncolytics. 15: 214-222. PMID 31890868 DOI: 10.1016/J.Omto.2019.10.005  0.475
2019 Wirsching HG, Zhang H, Szulzewsky F, Arora S, Grandi P, Cimino PJ, Amankulor N, Campbell JS, McFerrin L, Pattwell SS, Ene C, Hicks A, Ball M, Yan J, Zhang J, et al. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. Jci Insight. 4. PMID 31292299 DOI: 10.1172/Jci.Insight.128217  0.449
2018 Kennedy EM, Farkaly T, Goshert C, Colthart A, Behera P, Grzesik P, Grant K, Paglia M, Grandi P, Quéva C, Finer M, Lerner L. Abstract 5929: microRNA control of an oHSV vector allows for robust oncolysis and selective control of viral replication in normal tissues Cancer Research. 78: 5929-5929. DOI: 10.1158/1538-7445.Am2018-5929  0.4
2018 Hicks A, Grandi P, Paglia M, Miu J, Kwong C, Gursha J, Ball M, Yao W, Wambua D, Farkaly T, Grant K, Salta LV, Ponce L, Glorioso J, Queva C, et al. Abstract 4698: ONCR-1, a novel herpes simplex virus expressing MMP9 and ULBP3 transgenes, evokes potent oncolysis and development of antitumor immune responses Immunology. DOI: 10.1158/1538-7445.Am2018-4698  0.409
2018 Wirsching H, Zhang H, Grandi P, Arora S, Cimino PJ, Campbell JS, Szulzewsky F, Pattwell SS, Ene C, Kumasaka D, Pierce RH, Finer M, Queva C, Houghton AM, Holland E. TMIC-05. ABSCOPAL IMMUNE RESPONSE IN GLIOBLASTOMA ELICITED BY MIR124-ATTENUATED ONCOLYTIC HERPES SIMPLEX VIRUS 1 ARMED WITH UL16 BINDING PROTEIN 3 Neuro-Oncology. 20: vi256-vi257. DOI: 10.1093/Neuonc/Noy148.1065  0.366
2016 Zhang X, Rao A, Sette P, Deibert C, Pomerantz A, Kim WJ, Kohanbash G, Chang Y, Park Y, Engh J, Choi J, Chan T, Okada H, Lotze M, Grandi P, et al. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. Neuro-Oncology. PMID 27116977 DOI: 10.1093/Neuonc/Now061  0.377
2016 Choudhury SR, Hudry E, Maguire CA, Sena-Esteves M, Breakefield XO, Grandi P. Viral vectors for therapy of neurologic diseases. Neuropharmacology. PMID 26905292 DOI: 10.1016/J.Neuropharm.2016.02.013  0.31
2016 Rao A, Zhang X, Deibert C, Sette P, Chan T, Grandi P, Amankulor N. Abstract 3235: IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligands Cancer Research. 76: 3235-3235. DOI: 10.1158/1538-7445.Am2016-3235  0.437
2016 Sette P, Li A, Marzulli M, Leronni D, Zhang M, Goins W, Kaur B, Bolyard C, Amankulor N, Glorioso J, Grandi P. 520. Arming a Tumor Targeted Oncolytic HSV Vector with MMP9 for Enhanced Distribution and Killing Activity Molecular Therapy. 24: S207. DOI: 10.1016/S1525-0016(16)33329-9  0.49
2015 Leddon JL, Chen CY, Currier MA, Wang PY, Jung FA, Denton NL, Cripe KM, Haworth KB, Arnold MA, Gross AC, Eubank TD, Goins WF, Glorioso JC, Cohen JB, Grandi P, et al. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Molecular Therapy Oncolytics. 1: 14010. PMID 27119100 DOI: 10.1038/Mto.2014.10  0.506
2015 Wang PY, Swain HM, Kunkler AL, Chen CY, Hutzen BJ, Arnold MA, Streby KA, Collins MH, Dipasquale B, Stanek JR, Conner J, van Kuppevelt TH, Glorioso JC, Grandi P, Cripe TP. Neuroblastomas vary Widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility. Gene Therapy. PMID 26583803 DOI: 10.1038/Gt.2015.105  0.503
2015 Nakashima H, Kaufmann JK, Wang PY, Nguyen T, Speranza MC, Kasai K, Okemoto K, Otsuki A, Nakano I, Fernandez S, Goins WF, Grandi P, Glorioso JC, Lawler S, Cripe TP, et al. Histone deacetylase 6 inhibition enhances oncolytic viral replication in glioma. The Journal of Clinical Investigation. 125: 4269-80. PMID 26524593 DOI: 10.1172/Jci80713  0.517
2015 Han J, Chu J, Keung Chan W, Zhang J, Wang Y, Cohen JB, Victor A, Meisen WH, Kim SH, Grandi P, Wang QE, He X, Nakano I, Chiocca EA, Glorioso Iii JC, et al. CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells. Scientific Reports. 5: 11483. PMID 26155832 DOI: 10.1038/Srep11483  0.429
2015 Mazzacurati L, Marzulli M, Reinhart B, Miyagawa Y, Uchida H, Goins WF, Li A, Kaur B, Caligiuri M, Cripe T, Chiocca EA, Chiocca N, Amankulor N, Cohen JB, Glorioso JC, ... Grandi P, et al. Use of miRNA response sequences to block off-target replication and increase the safety of an unattenuated, glioblastoma-targeted oncolytic HSV. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 99-107. PMID 25200130 DOI: 10.1038/Mt.2014.177  0.393
2015 Li A, Marzulli M, Zhang M, Goins W, Kaur B, Bolyard C, Amankulor N, Leronni D, Sette P, Cohen J, Glorioso J, Grandi P. Abstract 3546: Arming a tumor targeted oncolytic herpes simplex sirus type 1 with matrix metalloproteinase 9 for enhanced vector distribution and killing activity Cancer Research. 75: 3546-3546. DOI: 10.1158/1538-7445.Am2015-3546  0.509
2015 Zhang X, Rao A, Deibert C, Sette P, Kim J, Lotze M, Grandi P, Amankulor N. Imps-45Idh Mutant Gliomas Escape Natural Killer Cell Immune Surveillance Through Downregulation Of Nkg2D Ligands Neuro-Oncology. 17. DOI: 10.1093/Neuonc/Nov217.44  0.392
2015 Sette P, Li A, Marzulli M, Zhang M, Goins W, Kaur B, Bolyard C, Caligiuri M, Cripe T, Chiocca A, Amankulor N, Glorioso J, Grandi P. ATPS-26ONCOLYTIC VECTORS BASED ON HSV FOR TREATMENT OF GBM Neuro-Oncology. 17: v23.4-v23. DOI: 10.1093/Neuonc/Nov204.26  0.516
2015 Sette P, Marzulli M, Leronni D, Zhang M, Goins W, Kaur B, Chelsea B, Cripe T, Chiocca A, Glorioso J, Amankulor N, Grandi P. 625. Arming a Tumor Targeted Oncolytic Herpes Simplex Virus Type 1 With Matrix Metalloproteinase 9 for Enhanced Vector Distribution and Killing Activity Molecular Therapy. 23: S248. DOI: 10.1016/S1525-0016(16)34234-4  0.521
2015 Currier M, Rizvi T, Nartker B, Chen D, Wang P, Patel A, Chaney K, Streby K, Kaur B, Grandi P, Glorioso J, Antonio Chiocca E, Ecsedy J, Conner J, Ratner N, et al. 432. Aurora A Kinase Inhibition Enhances Oncolytic Herpes Simplex Virotherapy in Models of Neuroblastoma Molecular Therapy. 23: S171. DOI: 10.1016/S1525-0016(16)34041-2  0.413
2014 Li A, Marzulli M, Mazzacurati L, Uchida H, Cohen J, Glorioso J, Grandi P. Abstract 703: Highly selective HSV virotherapy for glioblastoma Cancer Research. 74: 703-703. DOI: 10.1158/1538-7445.Am2014-703  0.481
2014 Zhang X, Chang Y, Li A, Glorioso JC, Grandi P, Lotze M, Amankulor N. Abstract 3669: IDH mutant glial cell resistance to natural killer cell cytotoxicity Cancer Research. 74: 3669-3669. DOI: 10.1158/1538-7445.Am2014-3669  0.415
2014 Brancho M, Chang Y, Zhang X, Okada H, Li A, Grandi P, Lotze M, Amankulor N. Ib-03Idh Mutant Gliomas Are Resistant To Natural Killer Cell-Mediated Cytolysis Neuro-Oncology. 16. DOI: 10.1093/Neuonc/Nou257.3  0.448
2014 Li A, Marzulli M, Mazzacurati L, Kaur B, Bolyard C, Cohen J, Goins W, Zhang M, Glorioso J, Grandi P. ET-34 * HIGHLY SELECTIVE HSV VIROTHERAPY FOR TREATMENT OF GLIOBLASTOMA Neuro-Oncology. 16: v87-v87. DOI: 10.1093/Neuonc/Nou255.34  0.477
2013 Uchida H, Chan J, Shrivastava I, Reinhart B, Grandi P, Glorioso JC, Cohen JB. Novel mutations in gB and gH circumvent the requirement for known gD Receptors in herpes simplex virus 1 entry and cell-to-cell spread. Journal of Virology. 87: 1430-42. PMID 23152509 DOI: 10.1128/Jvi.02804-12  0.446
2013 Uchida H, Marzulli M, Nakano K, Goins WF, Chan J, Hong CS, Mazzacurati L, Yoo JY, Haseley A, Nakashima H, Baek H, Kwon H, Kumagai I, Kuroki M, Kaur B, ... ... Grandi P, et al. Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 561-9. PMID 23070115 DOI: 10.1038/Mt.2012.211  0.539
2012 Reinhart B, Mazzacurati L, Forero A, Hong CS, Eguchi J, Okada H, Fellows W, Niranjan A, Cohen JB, Glorioso JC, Grandi P. Inhibition of Indoleamine-2,3-dioxygenase (IDO) in Glioblastoma Cells by Oncolytic Herpes Simplex Virus. Advances in Virology. 2012: 815465. PMID 22924042 DOI: 10.1155/2012/815465  0.546
2010 Uchida H, Chan J, Goins WF, Grandi P, Kumagai I, Cohen JB, Glorioso JC. A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. Journal of Virology. 84: 12200-9. PMID 20861246 DOI: 10.1128/Jvi.01633-10  0.464
2010 Grandi P, Fernandez J, Szentirmai O, Carter R, Gianni D, Sena-Esteves M, Breakefield XO. Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells. Cancer Gene Therapy. 17: 655-63. PMID 20508670 DOI: 10.1038/Cgt.2010.22  0.538
2010 Hong CS, Fellows W, Niranjan A, Alber S, Watkins S, Cohen JB, Glorioso JC, Grandi P. Ectopic matrix metalloproteinase-9 expression in human brain tumor cells enhances oncolytic HSV vector infection. Gene Therapy. 17: 1200-5. PMID 20463757 DOI: 10.1038/Gt.2010.66  0.473
2010 Frampton AR, Uchida H, von Einem J, Goins WF, Grandi P, Cohen JB, Osterrieder N, Glorioso JC. Equine herpesvirus type 1 (EHV-1) utilizes microtubules, dynein, and ROCK1 to productively infect cells. Veterinary Microbiology. 141: 12-21. PMID 19713056 DOI: 10.1016/J.Vetmic.2009.07.035  0.401
2010 Uchida H, Chan J, Goins WF, Grandi P, Kumagai I, Cohen JB, Glorioso JC. Abstract 584: Identification of mutations in HSV-1 envelope glycoprotein B that enhance retargeted infection Cancer Research. 70: 584-584. DOI: 10.1158/1538-7445.Am10-584  0.49
2009 Grandi P, Peruzzi P, Reinhart B, Cohen JB, Chiocca EA, Glorioso JC. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Review of Neurotherapeutics. 9: 505-17. PMID 19344302 DOI: 10.1586/Ern.09.9  0.519
2009 Uchida H, Shah WA, Ozuer A, Frampton AR, Goins WF, Grandi P, Cohen JB, Glorioso JC. Generation of herpesvirus entry mediator (HVEM)-restricted herpes simplex virus type 1 mutant viruses: resistance of HVEM-expressing cells and identification of mutations that rescue nectin-1 recognition. Journal of Virology. 83: 2951-61. PMID 19129446 DOI: 10.1128/Jvi.01449-08  0.475
2008 Li H, Baskaran R, Krisky DM, Bein K, Grandi P, Cohen JB, Glorioso JC. Chk2 is required for HSV-1 ICP0-mediated G2/M arrest and enhancement of virus growth. Virology. 375: 13-23. PMID 18321553 DOI: 10.1016/J.Virol.2008.01.038  0.433
2006 Bozac A, Berto E, Vasquez F, Grandi P, Caputo A, Manservigi R, Ensoli B, Marconi P. Expression of human immunodeficiency virus type 1 tat from a replication-deficient herpes simplex type 1 vector induces antigen-specific T cell responses. Vaccine. 24: 7148-58. PMID 16884834 DOI: 10.1016/J.Vaccine.2006.06.061  0.46
2006 McKee TD, Grandi P, Mok W, Alexandrakis G, Insin N, Zimmer JP, Bawendi MG, Boucher Y, Breakefield XO, Jain RK. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Research. 66: 2509-13. PMID 16510565 DOI: 10.1158/0008-5472.Can-05-2242  0.53
2006 Grandi P, Fernandez J, Szentirmai O, Carter R, Breakefield XO, Sena-Esteves M. 438. Targeting HSV-1 Virions for Specific Binding to Epidermal Growth Factor Receptor-VIII on Tumor Cells Molecular Therapy. 13. DOI: 10.1016/J.Ymthe.2006.08.504  0.536
2005 Grandi P, McKee TD, Mok W, Fernandez JL, Breakefield XO, Jain RK. 76. New Strategy To Improve Imaging and Retargeting of HSV-1 Vectors Molecular Therapy. 11. DOI: 10.1016/J.Ymthe.2005.06.054  0.406
2004 Grandi P, Spear M, Breakefield XO, Wang S. Targeting HSV amplicon vectors. Methods (San Diego, Calif.). 33: 179-86. PMID 15121173 DOI: 10.1016/J.Ymeth.2003.11.007  0.467
2004 Grandi P, Wang S, Schuback D, Krasnykh V, Spear M, Curiel DT, Manservigi R, Breakefield XO. HSV-1 virions engineered for specific binding to cell surface receptors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 9: 419-27. PMID 15006609 DOI: 10.1016/J.Ymthe.2003.12.010  0.479
2003 Spear MA, Schuback D, Miyata K, Grandi P, Sun F, Yoo L, Nguyen A, Brandt CR, Breakefield XO. HSV-1 amplicon peptide display vector. Journal of Virological Methods. 107: 71-9. PMID 12445940 DOI: 10.1016/S0166-0934(02)00193-3  0.441
2001 Caselli E, Grandi P, Argnani R, Balboni PG, Selvatici R, Manservigi R. Mice genetic immunization with plasmid DNA encoding a secreted form of HSV-1 gB induces a protective immune response against herpes simplex virus type 1 infection. Intervirology. 44: 1-7. PMID 11223713 DOI: 10.1159/000050023  0.382
Show low-probability matches.